Polyimide materials, as Kapton®, are widely used for flexible electronics substrates or as insulators, thanks to their wide range of thermal stability as well as excellent dielectric and mechanical properties. However, there are limitations in their processability and employment in new technologies due to their low solubility and deep amber staining, resulting from charge transfer interactions established between polymer rigid chains. Currently, researchers are focusing on designing resins with excellent thermal and chemical stability, transparent and colorless with a high processability in terms of viscosity and solubility. However, balancing among all those properties for this class of materials remains a big challenge today, as some of these properties seem to exclude others. In this episode, the focus will be on aliphatic anhydrides, which play a key role for the final polyimide’s properties enhancement. This will be explained by B.Sc. Sara Greco, a chemist working on this topic (as part of her master's thesis) in the R&D department of Valsynthese, a Swiss CDMO specialized in hazardous chemistry.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.